Date: 2013-09-11
Type of information: Collaboration agreement
Compound: advanced-therapy medicinal products
Company: CELLforCURE (France) Héma-Québec (Canada)
Therapeutic area: Regenerative medicine
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On September 11, 2013, CELLforCURE has signed its first international partnership agreement, with the Canadian non-profit organization Héma-Québec. This reciprocity agreement, with respect to the manufacture of medications based on stem cells, will provide CELLforCURE with a North American production partner approved by the U.S. and Canadian authorities.It will speed up access to the North American continent for both CELLforCURE’s products and those of its European customers. A cell production facility representing an investment of $21.5 million will be built in the Michelet innovation space within the territory of Québec City. This C?LAVIE complex, with an area of 3,716 square metres, will provide a controlled environment that complies with GMP. For the first few years, it will primarily be used to manufacture standardized cell and tissue products for clinical studies. Eventually, it will also ensure large-scale production of approved cellular medications. The work will start in 2014 and will benefit from contributions of $14.25M from Héma-Québec, $4.25M from the City of Québec and $3M from the Héma-Québec Foundation.
Financial terms:
Latest news:
